QCG
OPRX icon

Quadrant Capital Group’s OptimizeRx OPRX Stock Holding History

Quadrant Capital Group’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33
Closed -$554 – 2768
2022
Q4 		$554 Buy
+33
New +$571 ﹤0.01% 2609
2022
Q3 		– Sell
-8
Closed – – 2754
2022
Q2 		$0 Buy
+8
New +$237 ﹤0.01% 2674

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quadrant Capital Group's OPRX Position: Q1 2023 in Review

Quadrant Capital Group sold out of OptimizeRx (OPRX) in Q1 2023, closing a stake of 33 shares — an estimated $554 sold.

Quadrant Capital Group first reported a position in OPRX in Q2 2022 and held it in 2 quarters. The position peaked at $554 in Q4 2022. 110 funds tracked by Wall St. Rank hold OPRX as of Q1 2023.

  • Quadrant Capital Group reported no remaining OptimizeRx position as of Q1 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 33 OptimizeRx shares in Q1 2023, an estimated $554.
  • Quadrant Capital Group first reported a position in OptimizeRx in Q2 2022 and held it in 2 quarters.
  • Quadrant Capital Group's OptimizeRx position peaked at $554 in Q4 2022.
  • 110 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2023.

Based on Quadrant Capital Group's 13F filing for Q1 2023, filed 11 May 2023.